IP Library › Granted Patent US 8,524,670
Granted Patent B2
US 8,524,670 · App. 12/956,514 · Granted Sep 3, 2013

Engineered CXCL12 alpha locked dimer polypeptide

Inventors: Brian F. Volkman (Muskego, WI); Christopher T. Veldkamp (Milwaukee, WI); Francis C. Peterson (Racine, WI); Thomas Sakmar (New York, NY); Christoph H. Seibert (Frankfurt am Main, DE)
Assignees: Medical College of Wisconsin Research Foundation; The Rockefeller University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,670
App. No.
12/956,514
Granted
Sep 3, 2013
Kind
B2
Abstract

The present invention provides a novel CXCL12-α 2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Claims (7)

1. A method of treating blood cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α 2 locked dimer polypeptide, wherein the blood cancer cells express CXCR4.

2. The method of claim 1 wherein the subject is human.

3. A method of treating leukemia in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α 2 locked dimer polypeptide, wherein the leukemia cells express CXCR4.

4. A method of inhibiting migration of cancer cells in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α 2 locked dimer polypeptide, wherein the cancer cells express CXCR4.

5. The method of claim 4 wherein the cancer cells are selected from the group consisting of leukemia, lymphoma and myeloma.

6. A method of inhibiting migration of leukemia cells in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α 2 locked dimer polypeptide, wherein the leukemia cells express CXCR4.

7. The method of claim 1 wherein the blood cancer is selected from the group consisting of leukemia, lymphoma and myeloma.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 4, 2011
From: MEDICAL COLLEGE OF WISCONSIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026216/0722 →
Continuity (3)
Continuation 12380308 · Feb 26, 2009
Provisional Application 61067723 · Mar 1, 2008
Related Publication 20110091410A1 · Apr 21, 2011